Loading…
Employees: 203
Size Formycon (FYB.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $280M, the 205th largest of 205 Germany companies the cockpit tracks. Shares closed at €14.10 on 6 Nov 2026.
Performance Over six months the shares fell 25.8%, against -25.9% for the median peer and +2.6% for the Germany market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 18.3% over the last twelve months (peer median +1.7%); the operating margin is -25.5% (peer median 5.0%).
Valuation It trades at 3.4× enterprise value to sales against a peer median of 2.5× (8th most expensive of 20).
Capital Return on invested capital runs 9.9 points below its cost of capital (6.7% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €61.2M | €44.5M | €69.7M | €77.7M | €42.5M |
| Revenue growth | — | -36% | -10% | +83% | — |
| Gross profit | €14.0M | €3.58M | €14.8M | €23.3M | €12.1M |
| EBITDA | €10.2M | -€2.44M | -€13.2M | €1.46M | -€15.9M |
| Net income | -€25.1M | -€64.7M | -€126M | €75.8M | €36.0M |
| Free cash flow | -€5.62M | €10.8M | -€24.5M | -€10.4M | -€19.5M |
| Capital expenditure | €39.9M | €54.9M | €29.9M | €21.2M | €26.8M |
| Total debt | n/a | €9.56M | €10.6M | €29.5M | €49.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FYB.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.3% | -11.0% | 2nd lowest of 20 |
| 6-month return | -25.8% | -25.9% | 10th highest of 20 |
| Distance from 52-week high | -47.7% | -45.8% | 9th lowest of 20 |
| Revenue growth (TTM) | +18.3% | +1.7% | 5th highest of 19 |
| Operating margin | -25.5% | 5.0% | 5th lowest of 20 |
| EV / Sales | 3.4× | 2.5× | 8th most expensive of 20 |
| ROIC minus cost of capital | -9.9 pp | -5.0 pp | 5th lowest of 19 |
| EV / EBITDA | 20.2× | 12.3× | 4th most expensive of 9 |
| Net debt / EBITDA | -4.2× | 2.0× | least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Formycon FYB.DE | Germany | $280M | -26% | +18% | -26% | 3.4× | n/a | n/a |
| Fuji Pharma 4554.T | Japan | $294M | -19% | +20% | 12% | 1.1× | -6.8% | +8.9% |
| Shinpoong Pharmaceutical 019170.KS | South Korea | $300M | -32% | +6% | 1% | 1.6× | 39.9% | +3.5% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | 3.3× | 10.1% | +0.6% |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 1.0× | -0.1% | -13.7% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | 1.1× | n/a | n/a |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | 66.5× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 1.7× | 5.5% | +62.1% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 3.1× | -16.7% | +5.4% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | 2.5× | 5.7% | -0.3% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | 2.5× | 2.7% | +2.3% |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | 1.2× | 31.5% | +7.4% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |